PSMA therapy falls under the category of “theranostics,” a new oncology paradigm combining “therapy” and “diagnostics.” This means that the same type of process used in diagnostics is also used in treatment. In other words, PSMA therapy is similar to PSMA PET imaging, just with a different type of radiation that can damage cells.

PSMA therapy, also called PSMA-targeted radioligand therapy, uses a small molecule called a ligand to bind to the PSMA on cells. Attached to this ligand is a radioactive isotope called lutetium-177, which releases once the ligand latches to the protein, delivering small doses of cancer-killing radiation exactly where…

Read the full article at EVERYDAYHEALTH.COM